Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

Funding Empowers 53 Organizations to Enhance Education, Care and Support Services –

Gilead Foundation today announced a commitment of more than $3 million in new grants to help address critical gaps in education, care delivery and support services for people affected by metastatic breast cancer (mBC). Building on more than $21 million in support since 2021, funding distributed through the Gilead Foundation advances efforts to improve access to breast cancer education and care nationwide, complementing Gilead Sciences' broader commitment to creating sustainable change for the breast cancer community.

Breast cancer is one of the most common cancers affecting women in the United States, with an estimated 168,000 people impacted by disease that has spread to other parts of the body (metastatic disease). While treatment options have advanced significantly, the five-year relative survival rate for people with mBC is 29%, highlighting an urgent need for improved education and integrated support services to help patients navigate complex treatment decisions and improve outcomes.

The 2025 grants will support 23 nationwide programs led by 53 organizations to advance breast cancer awareness and education. These programs will provide emotional and mental health support along with health literacy tools, educational resources, and improved access to nutrition. They will also offer community workshops, create new ways to provide care, train providers in cross-cultural awareness, and help patients understand their treatment options.

"The organizations we selected showcased innovative ideas with a strong commitment to patient-centered education, support, and access to care while creating sustainable models for lasting impact," said Anu Osinusi, Vice President, Virology at Gilead Sciences and Board Member, Gilead Foundation. "We are proud to champion these efforts, which collaboratively bring together 53 different organizations, an approach we believe is essential to supporting patients and their caregivers navigating metastatic breast cancer."

Gilead Foundation's oncology grants are a cornerstone of its commitment to addressing immediate needs while strengthening care systems for the future. By fostering partnerships across diverse organizations, the Foundation collaborates to strengthen care systems and improve care quality for patients and communities nationwide.

"Gilead Foundation's investment makes a meaningful difference in the lives of the women we serve. It allows the Charlotte Maxwell Clinic to expand free wrap-around services while helping build coordinated care systems with the Women's Cancer Resource Center," said Ray Rieder, interim Executive Director, Charlotte Maxwell Clinic in Oakland, Calif. "Together, we can reach women sooner, support them more comprehensively, and design a system that continues to meet their needs long after the grant period. We are truly grateful for Gilead Foundation's partnership in this transformative work."

Key Facts:

  • Research shows that patients who receive navigation services have a shorter time to diagnosis and treatment, a better understanding of their condition and the treatment process and are more likely to complete their respective course of treatment. ( Cancer )
  • Findings show how health literacy, the ability to find, understand, and use health information to make informed decisions, is linked to poorer outcomes and higher mortality rates among people with advanced-stage breast cancer. ( Cancer )
  • Findings indicate the importance of providing women with mBC with nutrition information that is tailored to their disease to help address nutritional problems and uncertainty regarding nutritional strategies. ( Cancer Nursing )

Lead Grantee Recipients:

  1. African Women's Cancer Awareness Association
  2. Asociacion Latina de Asistencia Y Prevencion Del Cancer De Mama
  3. Bebashi - Transition To Hope
  4. Breastcancer.org
  5. Cancer Support Community Los Angeles
  6. Emory University
  7. Family Reach
  8. FORCE - Facing Our Risk of Cancer Empowered
  9. Living Beyond Breast Cancer
  10. Mary Bird Perkins Cancer Center
  11. Nueva Vida
  12. SHARE Cancer Support
  13. Sharsheret
  14. Sisters Network ®
  15. Social and Environmental Entrepreneurs (SEE)
  16. SurvivingBreastCancer.org
  17. T O U C H Therapy Inc
  18. Ellie Fund
  19. Triage Cancer ®
  20. Unite For HER
  21. Women's Cancer Resource Center
  22. Young Survival Coalition
  23. Latinas Contra Cancer

About the Gilead Foundation

The Gilead Foundation is a nonprofit organization that works to create a thriving health ecosystem. The Gilead Foundation takes a holistic approach to mitigate the root causes of health inequities by providing resources to organizations that empower people with the skills to be their own best advocate and create systems of support that strengthen communities, classrooms and workplaces.

About Gilead Sciences

Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Gilead, Gilead Foundation and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com , follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

Elizabeth Baxter, Media
public_affairs@gilead.com

Jacquie Ross, Investors
investor_relations@gilead.com

News Provided by Business Wire via QuoteMedia

GILD
The Conversation (0)
Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, is delighted to announce the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.Paul Carter is a highly... Keep Reading...
CHMP Adopts Positive Opinion Recommending Hepcludex®  for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

CHMP Adopts Positive Opinion Recommending Hepcludex® for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

-- If Granted by the European Commission, Hepcludex will Become the Only Approved Treatment for HDV in the EU -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive... Keep Reading...
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated... Keep Reading...
Gilead Sciences Announces First Quarter 2023 Financial Results

Gilead Sciences Announces First Quarter 2023 Financial Results

Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.7 billion Biktarvy Sales Increased 24% Year-Over-Year to $2.7 billion Oncology Sales Increased 59% Year-Over-Year to $670 million Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first... Keep Reading...
Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report. This is an evolution of our traditional Year in Review, and uses the ESG framework to highlight the successes and achievements of the prior yearThough the report itself is new, our... Keep Reading...
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News